海外の治験の状況「1」での検索結果
11979件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- The blood vessel protecting cell response to exercise in people with and without type 1 diabetes
- Type 1 diabetes Nutritional, Metabolic, Endocrine Type 1 diabetes mellitus
- United Kingdom
- 2019-08-23
Not recruiting
- Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia
- Advanced Solid Tumors;Chronic Lymphocytic Leukemia;Advanced Solid Tumors;Chronic Lymphocytic Leukemia;Advanced Solid Tumors;Chronic Lymphocytic Leukemia
- Germany
- 2014-12-10
Authorised
- study to investigate cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing after an initial response to a 1st-line cetuximab-containing therapy and a standard 2nd-line.
- metastatic colonrectal cancer KRAS, NRAS and BRAF wild type. MedDRA version: 17.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-05-16
Authorised
- A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 17.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Authorised
- Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 16.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Not Recruiting
- Phase I study of S 78454 in the treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome
- Acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome. Cancer Acute myeloid leukemia
- France
- 2013-12-09
Not recruiting
- Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Locally Advanced or Metastatic Breast Cancer;Locally Advanced or Metastatic Breast Cancer;Locally Advanced or Metastatic Breast Cancer;Locally Advanced or Metastatic Breast Cancer
- Australia, Italy, United States
- 2008-03-05
Authorised
- VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
- FIGO Stage III-IV serous epithelial ovarian carcinoma
- Finland
- 2005-09-12
Authorised
- A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interleukin-2 in patients with higher risk myelodysplastic syndromes (MDS) who achieved hematological response to azacitidine. - GFM-Aza-ceplene
- Myelodysplastic syndromes MedDRA version: 12.1 Level: LLT Classification code 10028533 Term: Myelodysplastic syndrome
- France
- 2010-07-29
Not Recruiting
- A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Germany, United Kingdom, United States
- 2012-10-31
Recruiting
- Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
- Gastric Cancer;Oesophageal Cancer;Breast Cancer;Squamous Cell Carcinoma of the Lung
- United Kingdom
- 2013-01-31
Not recruiting
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
- Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1
- Belgium, Brazil, Canada, Croatia, Czech Republic, India, Israel, Macedonia, The Former Yugoslav Republic of, Poland, Russian Federation, Serbia, Slovenia, South Africa, Spain, United States
- 2013-04-16
Authorised
- Study of the possibility to increase remnant insulin production in patients with type 1 diabetes using the glucagon-like peptide 1 mimicking drug liraglutide
- Beta-cell function in C-peptide positive type 1 diabetes;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Sweden
- 2015-08-11
Not Recruiting
- Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.
- Relapsing-remitting multiple sclerosis (RR MS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Belgium, Brazil, Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Mexico, Slovakia, Spain, United Kingdom
- 2015-08-06
Not recruiting
- A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Type1 Diabetes Mellitus;Type1 Diabetes Mellitus;Type1 Diabetes Mellitus;Type1 Diabetes Mellitus
- Germany
- 2016-09-20
Authorised
- Phase II study in patients suffering from metastatic breast cancer Her2neg, The Line, randomized (1:1) with two arms.
- patients wiyh metastatic breast cancer her2 negative first line treatment MedDRA version: 14.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2012-07-23
Authorised
- Individualised choise of 1.line chemotherapy of metastatic colo-rectal cancer. Can the blood test: TIMP-1 help the doctor to choose the best chemotherapy for the individual patient?
- Metastatic colon or rectal cancer MedDRA version: 14.1 Level: PT Classification code 10027457 Term: Metastases to liver System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: PT Classification code 10010035 Term: Colorectal cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Denmark
- 2012-04-18
Not recruiting
- A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
- Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma;Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma;Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma;Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma
- Belgium, Lithuania, Spain
- 2013-09-23
Authorised
- A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in patients with rheumatoid arthritis who have a high interferon signature (TarIFNiRA)
- High IFN siganture in patients with rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Austria, Italy, Switzerland
- 2017-08-17
Not Recruiting
- Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND
- Marfan Syndrome MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome
- Italy
- 2008-03-17